US Patent 11186840 CTLA-4 aptamer conjugates
Patent 11186840 was granted and assigned to City of Hope on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 2 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+359 characters)
Article
Patent abstract
Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Andreas Herrmann0
Hua Yu0
Marcin Tomasz Kortylewski0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111868400
Date of Patent
November 30, 2021
0Patent Application Number
168929950
Date Filed
June 4, 2020
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Dec, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11186840 CTLA-4 aptamer conjugates
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11186840
Date of patent
November 30, 2021
Patent application number
16892995
Date Filed
June 4, 2020
Patent primary examiner
Find more entities like US Patent 11186840 CTLA-4 aptamer conjugates
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
